Medicine (RMH) - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/193

Filters

2020 - 2021 3
3
Reset filters

Settings
Statistics
Citations
Author: Conyers, Rachel × End date: 2021 × Start date: 2020 ×

Search Results

Now showing 1 - 3 of 3
  • Item
    No Preview Available
    Bone Marrow Transplant Society of Australia and New Zealand COVID-19 consensus position statement
    Hamad, N ; Gottlieb, D ; Ritchie, D ; Kennedy, G ; Watson, AM ; Greenwood, M ; Doocey, R ; Perera, T ; Spencer, A ; Wong, E ; O'Brien, T ; Shaw, P ; Conyers, R ; Cole, T ; Milliken, S ; Bardy, P ; Larsen, S ; Lai, H ; Butler, A ; Fraser, C ; Bajel, A ; Butler, J ; Kerridge, I ; Purtill, D (WILEY, 2020-06)
  • Item
    No Preview Available
    Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance
    Weinkove, R ; McQuilten, ZK ; Adler, J ; Agar, MR ; Blyth, E ; Cheng, AC ; Conyers, R ; Haeusler, GM ; Hardie, C ; Jackson, C ; Lane, SW ; Middlemiss, T ; Mollee, P ; Mulligan, SP ; Ritchie, D ; Ruka, M ; Solomon, B ; Szer, J ; Thursky, KA ; Wood, EM ; Worth, LJ ; Yong, MK ; Slavin, MA ; Teh, BW (WILEY, 2020-06)
    INTRODUCTION: A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. Community transmission of COVID-19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic. MAIN RECOMMENDATIONS: During the COVID-19 pandemic: In patients with cancer with fever and/or respiratory symptoms, consider causes in addition to COVID-19, including other infections and therapy-related pneumonitis. For suspected or confirmed COVID-19, discuss temporary cessation of cancer therapy with a relevant specialist. Provide information on COVID-19 for patients and carers. Adopt measures within cancer centres to reduce risk of nosocomial SARS-CoV-2 acquisition; support population-wide social distancing; reduce demand on acute services; ensure adequate staffing; and provide culturally safe care. Measures should be equitable, transparent and proportionate to the COVID-19 threat. Consider the risks and benefits of modifying cancer therapies due to COVID-19. Communicate treatment modifications, and review once health service capacity allows. Consider potential impacts of COVID-19 on the blood supply and availability of stem cell donors. Discuss and document goals of care, and involve palliative care services in contingency planning. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT: This interim consensus guidance provides a framework for clinicians managing patients with cancer during the COVID-19 pandemic. In view of the rapidly changing situation, clinicians must also monitor national, state, local and institutional policies, which will take precedence. ENDORSED BY: Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australian and New Zealand Children's Haematology/Oncology Group; Australia and New Zealand Society of Palliative Medicine; Australasian Society for Infectious Diseases; Bone Marrow Transplantation Society of Australia and New Zealand; Cancer Council Australia; Cancer Nurses Society of Australia; Cancer Society of New Zealand; Clinical Oncology Society of Australia; Haematology Society of Australia and New Zealand; National Centre for Infections in Cancer; New Zealand Cancer Control Agency; New Zealand Society for Oncology; and Palliative Care Australia.
  • Item
    Thumbnail Image
    Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement
    Hamad, N ; Ananda-Rajah, M ; Gilroy, N ; MacIntyre, R ; Gottlieb, D ; Ritchie, D ; Harrison, S ; Kennedy, G ; Watson, AM ; Greenwood, M ; Doocey, R ; Perera, T ; Spencer, A ; Wong, E ; O'Brien, T ; Shaw, P ; Conyers, R ; Milliken, S ; Bardy, P ; Larsen, S ; Ho, PJ ; Lai, H ; Bajel, A ; Butler, J ; Tiley, C ; D'Rozario, J ; Johnston, A ; Cochrane, T ; Mills, T ; Irving, I ; Pullon, H ; Purtill, D (WILEY, 2021-08)
    Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives of all adult and paediatric allogeneic bone marrow transplant and cellular therapy (TCT) centres as well as representatives from autologous transplant only centres in Australia and New Zealand collaborated with infectious diseases specialists with expertise in TCT on this consensus position statement regarding COVID-19 vaccination in TCT patients in Australia and New Zealand. It is our recommendation that TCT patients, should have expedited access to high-efficacy COVID-19 vaccines given that these patients are at high risk of morbidity and mortality from COVID-19 infection. We also recommend prioritising vaccination of TCT healthcare workers and household members of TCT patients. Vaccination should not replace other public health measures in TCT patients given the effectiveness of COVID-19 vaccination in TCT patients is unknown. Furthermore, given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.